Abstract
To compare preoperative intestinal trefoil factor 3 (TFF3), allograft inflammatory factor-1 (AIF-1) and calgizzarin (S100-A11) serum levels in patients with endometrial cancer, endometrial hyperplasia and in healthy female controls. Serum levels of TFF3, S100- A11 and AIP-1 were analyzed in 98 consecutive patients with histologically verified endometrial cancer, in 43 patients with endometrial hyperplasia diagnosed during hysteroscopy and 24 controls with benign disease. Results were correlated with urinary neopterin/creatinine ratio, serum kynurenine, tryptophan, retinol, alpha-tocopherol, vitamin D, citrulline, C-reactive protein, interleukin-6 and clinical characteristics. S100-A11, and AIF-1 levels were higher in endometrial hyperplasia patients than in controls, and also significantly higher in endometrial cancer than in patients with endometrial hyperplasia. Serum concentrations of TFF3 and S100-A11 were associated with tumor stage and lymph node status. TFF3 exhibited positive correlation with age, IL-6, vitamin D, kynurenine, urinary neopterin/creatinine ratio and kynurenine/tryptophan ratio. S100-A11, as well as AIF-1 correlated positively with Il-6 and TFF3. TFF3, S100-A11 and AIF-1 represent potential biomarkers in patients with endometrial cancer. TFF3 and S100-A11 increase with tumor stage and lymph node involvement, reflecting higher tumor mass that is also associated with increased concentration of biomarkers of immune dysfunction.
References
1. R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.10.3322/caac.21208Search in Google Scholar
2. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366(9484):491-505.10.1016/S0140-6736(05)67063-8Search in Google Scholar
3. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987;60(8 Suppl):2035-41.10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8Search in Google Scholar
4. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009;105(2):109.10.1016/j.ijgo.2009.02.010Search in Google Scholar
5. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707-16.10.1093/jnci/djn397Search in Google Scholar
6. Kyrgiou M, Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 2017;356:j477.10.1136/bmj.j477Search in Google Scholar
7. Jorgensen KH, Thim L, Jacobsen HE. Pancreatic spasmolytic polypeptide (PSP): I. Preparation and initial chemical characterization of a new polypeptide from porcine pancreas. Regul Pept. 1982;3(3-4):207-19.10.1016/0167-0115(82)90126-4Search in Google Scholar
8. Suemori S, Lynch-Devaney K, Podolsky DK. Identification and characterization of rat intestinal trefoil factor: tissue- and cellspecific member of the trefoil protein family. Proc Natl Acad Sci USA. 1991;88(24):11017-21.10.1073/pnas.88.24.11017Search in Google Scholar
9. Thim L. A new family of growth factor-like peptides. ‘Trefoil’ disulphide loop structures as a common feature in breast cancer associated peptide (pS2), pancreatic spasmolytic polypeptide (PSP), and frog skin peptides (spasmolysins). FEBS Lett. 1989;250(1):85-90.10.1016/0014-5793(89)80690-8Search in Google Scholar
10. Bignotti E, Ravaggi A, Tassi RA, Calza S, Rossi E, Falchetti M, et al. Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. Br J Cancer. 2008;99(5):768-73.10.1038/sj.bjc.6604546Search in Google Scholar
11. Longman RJ, Thomas MG, Poulsom R. Trefoil peptides and surgical disease. Br J Surg. 1999;86(6):740-8.10.1046/j.1365-2168.1999.01131.xSearch in Google Scholar
12. andai M, Kariya M, Fukuhara K, Sakaguchi M, et al. Increased expression of calcium-binding protein S100 in human uterine smooth muscle tumours. Mol Hum Reprod. 2004;10(10):735-42.10.1093/molehr/gah100Search in Google Scholar
13. Taverna D, Pollins AC, Sindona G, Caprioli RM, Nanney LB. Imaging mass spectrometry for assessing cutaneous wound healing: analysis of pressure ulcers. J Proteome Res. 2015;14(2):986-96.10.1021/pr5010218Search in Google Scholar
14. Deininger MH, Meyermann R, Schluesener HJ. The allograft inflammatory factor-1 family of proteins. FEBS Lett. 2002;514(2-3):115-21.10.1016/S0014-5793(02)02430-4Search in Google Scholar
15. Utans U, Arceci RJ, Yamashita Y, Russell ME. Cloning and characterization of allograft inflammatory factor-1: a novel macrophage factor identified in rat cardiac allografts with chronic rejection. J Clin Invest. 1995;95(6):2954-62.10.1172/JCI118003Search in Google Scholar PubMed PubMed Central
16. Zhao YY, Yan DJ, Chen ZW. Role of AIF-1 in the regulation of inflammatory activation and diverse disease processes. Cell Immunol. 2013;284(1-2):75-83.10.1016/j.cellimm.2013.07.008Search in Google Scholar PubMed
17. Zezulova M, Bartouskova M, Hlidkova E, Adam T, Kujovska Krcmova L, Cervinkova B, et al. Citrulline as a biomarker of gastrointestinal toxicity in patients with rectal carcinoma treated with chemoradiation. Clin Chem Lab Med. 2016;54(2):305-14.10.1515/cclm-2015-0326Search in Google Scholar PubMed
18. Pilka R, Marek R, Adam T, Kudela M, Ondrova D, Neubert D, et al. Systemic Inflammatory Response After Open, Laparoscopic and Robotic Surgery in Endometrial Cancer Patients. Anticancer Res. 2016;36(6):2909-22.Search in Google Scholar
19. Melichar B. Laboratory medicine and medical oncology: the tale of two Cinderellas. Clin Chem Lab Med. 2013;51:99-112.10.1515/cclm-2012-0496Search in Google Scholar PubMed
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.10.1016/j.cell.2011.02.013Search in Google Scholar PubMed
21. Melichar B, Freedman RS. Immunology of the peritoneal cavity: Relevance for host-tumor relation. Int J Gynecol Cancer. 2002;12:3-17.10.1046/j.1525-1438.2002.01093.xSearch in Google Scholar PubMed
22. Freedman RS, Vadhan-Raj S, Butts C, Savary C, Melichar B, Verschraegen C, et al. Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin Cancer Res. 2003;9:5228-37.Search in Google Scholar
23. Melichar B, Gregor J, Solichova D, Lukes J, Tichy M, Pidrman V. Increased urinary neopterin in acute myocardial infarction. Clinical Chemistry. 1994;40:338-9.10.1093/clinchem/40.2.338Search in Google Scholar
24. Solichova D, Melichar B, Blaha V, Klejna M, Vavrova J, Palicka V, et al. Biochemical profile and survival in nonagenarians. Clin Biochem. 2001;34:563-9.10.1016/S0009-9120(01)00261-2Search in Google Scholar
25. Melichar B, Solichova D, Freedman RS. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer. 2006;16(1):240-52.10.1111/j.1525-1438.2006.00294.xSearch in Google Scholar PubMed
26. Melichar B, Solichova D, Melicharova K, Malirova E, Cermanova M, Zadak Z. Urinary neopterin in patients with advanced colorectal carcinoma. Int J Biol Markers. 2006;21(3):190-8.10.1177/172460080602100309Search in Google Scholar PubMed
27. Melichar B, Jandik P, Krejsek J, Solichova D, Drahosova M, Skopec F, et al. Mitogen-induced lymphocyte proliferation and systemic immune activation in cancer patients. Tumori. 1996;82(3):218-20.Search in Google Scholar
28. Melichar B, Nash MA, Lenzi R, Platsoucas CD, Freedman RS. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin Exp Immunol. 2000;119(1):19-27.10.1046/j.1365-2249.2000.01105.xSearch in Google Scholar PubMed PubMed Central
29. Melichar B, Touskova M, Solichova D, Kralickova P, Kopecky O. CD4+ T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours. Scand J Clin Lab Invest. 2001;61:363-70.10.1080/003655101316911404Search in Google Scholar PubMed
30. Melichar B, Ferrandina G, Verschraegen CF, Loercher A, Abbruzzese JL, Freedman RS. Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. Clinical Cancer Research. 1998;4:3069-76.Search in Google Scholar
31. Burke F, Knowles RG, East N, Balkwill FR. The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gama in vivo. International Journal of Cancer. 1995;60:115 - 22.10.1002/ijc.2910600117Search in Google Scholar PubMed
32. Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, et al. Indoleamin 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. International Journal of Cancer. 2002;101:151 - 5.10.1002/ijc.10645Search in Google Scholar PubMed
33. Melichar B, Kohout P, Bratova M, Solichova D, Kralickova P, Zadak Z. Intestinal permeability in patients with chemotherapyinduced stomatitis. J Cancer Res Clin Oncol. 2001;127(5):314-8.10.1007/s004320000209Search in Google Scholar PubMed
34. Melichar B, Nemcova I. Eye complications of cetuximab therapy. Eur J Cancer Care (Engl). 2007;16(5):439-43.10.1111/j.1365-2354.2006.00763.xSearch in Google Scholar PubMed
35. Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, et al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann Oncol. 2012;23(12):3137-43.10.1093/annonc/mds145Search in Google Scholar PubMed
36. Zezulova M, Bartouskova M, Hlidkova E, Adam T, Kujovska Krcmova L, Cervinkova B, et al. Citrulline as a biomarker of gastrointestinal toxicity in patients with rectal carcinoma treated with chemoradiation. Clin Chem Lab Med. 2016;54:305-14.10.1515/cclm-2015-0326Search in Google Scholar PubMed
© 2018
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
